This enrichment is driven by disruptive mutations in MLH1, MSH2, PMS2 and MSH6, but also POLE2, and POT1 and MRE11A genes hitherto not previously implicated in CRC susceptibility. The gene discussed is MSH2; the disease is colorectal carcinoma.